Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17).

Mlineritsch B, Tausch C, Singer C, Luschin-Ebengreuth G, Jakesz R, Ploner F, Stierer M, Melbinger E, Menzel C, Urbania A, Fridrik M, Steger G, Wohlmuth P, Gnant M, Greil R Breast Cancer Res Treat. 2008 Nov,112(1):203-13. Epub 2007 Dec 22.

Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer.

Arkenau HT, Graeven U, Kubicka S, Grothey A, Englisch-Fritz C, Kretzschmar A, Greil R, Freier W, Seufferlein T, Hinke A, Schmoll HJ, Schmiegel W, Porschen R Clin Colorectal Cancer. 2008 Jan,7(1):60-4.

Biweekly oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. A first-line multicenter phase II trial of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT).

Wöll E, Kühr T, Eisterer W, Gattringer K, Greil R, Zabernigg A, Hilbe W, Thaler J. Anticancer Res. 2008 Sep-Oct,28(5B):2901-5.

Mitochondrial phosphate-carrier deficiency: a novel disorder of oxidative phosphorylation.

Mayr JA, Merkel O, Kohlwein SD, Gebhardt BR, Böhles H, Fötschl U, Koch J, Jaksch M, Lochmüller H, Horvath R, Freisinger P, Sperl W. American Journal of Human Genetics. 2007 Mar,80(3):478-84. Epub 2007 Jan 10.

Zell- und Molekularbiologie.

Tinhofer I. in Lymphoproliferative Erkrankungen R.Greil Uni-Med Science, Seite 29 – 41

Diagnostic algorithms, monitoring prognostication and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform.

Valent P, Lion T, Wolf D, Sillaber C, Agis H, Petzer A, Lang A, Kalhs P, Geissler D, Greil R, Linkesch W, Burgstaller S, Thaler J, Gastl G. Wien Klin Wochenschr. 2008,120(21-22):697-709. doi: 10.1007/s00508-008-1100-8.

Therapy of antibody-mediated factor VIII deficiency by immunosuppressive therapy containing cyclophosphamide, dexamethasone and rituximab: A case report

Thoedtmann, R, Rosenlechner, S, Unger, J, Patsch, W, Greil, R HAEMATOL-HEMATOL J. 2007, 92: 546-546.

MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukaemia but can be preferentially targeted by the MDM2 inhibitor Nutlin-3a

Tinhofer, I, Gryshchenko, I, Stoecher, M, Hofbauer, S, Daniel, PT, Greil, R EJC SUPPL. 2007, 5(4): 347-347.

Incidence and other aspects of myelodysplastic syndrome in the Austrian federal state Salzburg

Kemmerling, R, Neuretter, D, Faber, V, Stocher, M, Greil, R, Dietze, O PATHOL RES PRACT. 2007, 203(5): 392-392.

Morbus Hodgkin.

Greil, R, In: Greil, R (Ed.) editors(s). Lymphoproliferative Erkrankungen..